BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Moodys
Fuji
UBS
Harvard Business School
Covington
Julphar
Baxter
Chinese Patent Office

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,415,085

« Back to Dashboard

Which drugs does patent 9,415,085 protect, and when does it expire?

Patent 9,415,085 protects FIRMAGON and is included in one NDA.

This patent has sixty-nine patent family members in twenty-two countries.
Summary for Patent: 9,415,085
Title:Method of treating prostate cancer with GnRH antagonist
Abstract: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
Inventor(s): van der Meulen; Egbert A. (Dalby, SE), Tanko; Laszlo Balazs (Basel, CH)
Assignee: FERRING B.V. (Hoofddorp, NL)
Application Number:13/458,330
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 9,415,085

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,415,085

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,841,081 Method of treating metastatic stage prostate cancer ➤ Subscribe
9,579,359 Method of treating prostate cancer with GnRH antagonist ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,415,085

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 107412726 ➤ Subscribe
Cyprus 1115561 ➤ Subscribe
Cyprus 1116289 ➤ Subscribe
Cyprus 1116341 ➤ Subscribe
Denmark 2249859 ➤ Subscribe
Denmark 2505204 ➤ Subscribe
Denmark 2650012 ➤ Subscribe
Eurasian Patent Organization 200901074 ➤ Subscribe
Eurasian Patent Organization 017582 ➤ Subscribe
Eurasian Patent Organization 200901075 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Novartis
Cipla
Cantor Fitzgerald
Medtronic
Cerilliant
McKinsey
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot